论文部分内容阅读
目的研究2型糖尿病患者接受双相门冬胰岛素(诺和锐30)短期强化治疗的剂量及其影响因素。方法空腹血糖≥10 mmol/L,糖化血红蛋白(HbA1C)≥8%的70例2型糖尿病患者,采用双相门冬胰岛素餐时皮下注射,按需配给二甲双胍250 mg,3次/d口服控制餐后血糖,使患者餐前血糖控制在4.4～6.0 mmol/L,3餐后2 h血糖控制在4.4～10.0 mmol/L。记录血糖最初达标时的双相门冬胰岛素剂量、血糖达标时间,比较血糖、体质量指数及病程时间不同患者的双相门冬胰岛素用量的差异。结果控制达标时,受试患者平均餐前血糖得以控制的时间为(10±3)d,平均餐后2 h血糖得以控制的时间为(8.0±2.5)d,双相门冬胰岛素的平均用量为0.4 U.kg-1.d-1,空腹血糖≥11 mmol/L组双相门冬胰岛素所用剂量明显大于空腹血糖10～11 mmol/L组,体质量指数低于24 kg/m2组,双相门冬胰岛素剂量明显大于体质量指数≥24 kg/m2组,病程长者双相门冬胰岛素剂量明显高于病程短者(P均<0.05)。结论双相门冬胰岛素治疗2型糖尿病患者强化期用药剂量平均为0.4 U.kg-1.d-1,应用双相门冬胰岛素进行强化治疗应根据患者体质量、基线血糖,病程长短调整用药剂量。
Objective To study the dose and influencing factors of short-term intensive treatment of patients with type 2 diabetes receiving biphasic insulin aspart (Novo-Rui 30). Methods Seventy patients with type 2 diabetes with fasting blood glucose ≥10 mmol / L and glycosylated hemoglobin (HbA1C) ≥8% were given subcutaneous injections of biphasic insulin aspart and 250 mg of metformin as required and oral controlled meal 3 times / d After blood glucose, the patient’s pre-prandial blood glucose control in 4.4 ~ 6.0 mmol / L, 3 h after 2 h blood glucose control in 4.4 ~ 10.0 mmol / L. Record the initial bipolar insulin dose, blood glucose compliance time, blood glucose, body mass index and duration of different patients biphasic insulin aspart insulin dosage differences. Results When the control standard was reached, the average pre-prandial glycemic control time was (10 ± 3) days and the mean postprandial 2-hour postprandial glycemic control time was (8.0 ± 2.5) days. The average dosage of biphasic insulin aspart The dosage of Biphasic insulin aspart was significantly higher than that of fasting blood glucose (10-11 mmol / L) and the body mass index (BMI) was lower than 24 kg / m2 at 0.4 U.kg-1.d- Biphasic insulin aspart was significantly higher than the body mass index ≥24 kg / m2 group, the dose of biphasic insulin aspart was significantly higher than the shorter duration of disease (P all <0.05). Conclusion Aspartic insulin treatment of type 2 diabetes mellitus patients with an average dosage of 0.4 U.kg-1.d-1, the application of biphasic insulin aspart in the intensive treatment should be based on the patient’s body weight, baseline blood glucose, duration of medication adjustment dose.